Biogen Idec Commits $10M to New ALS Research Consortium

Biogen Idec recently announced the creation of a new ALS focused academic research consortium with the long-term goal of identifying potential drugs to treat ALS. The Chief Scientific Officer at Biogen Idec, Spyros Artavanis-Tsakonas, said “We believe that taking a holistic approach that explores the many variables involved in the development and progression of ALS will speed our ability to identify viable drug targets that can be moved into testing.” The consortium will include researcher groups from Yale University, Harvard Medical School, Columbia University, The Rockefeller University and the Harvard Stem Cell Institute.

Click here to read more.

Share this: